Cellestia Biotech
Business Services · 11-50 Employees
View Company Info for Free
Overview
Phone Number
+41 616332980Website
www.cellestia.comRevenue
$5.3 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Cellestia Biotech
Cellestia is a clinical stage R&D company developing innovative first-in-class therapies to control and modulate pathogenic gene expression in multiple disease areas by selective inhibition of transcription factors in the cell nucleus. The lead compound CB-103 has advanced to Phase 2 successfully treating patients with multi-drug resistant cancers. Further, Cellestia is advancing a rich R&D pipeline of novel transcription factor inhibitors, in oncology, auto-immune and inflammatory disorders, having achieved animal in-vivo proof of concept for several new targets. Cellestia was founded in 2014 as a spin-off from EPFL, Lausanne, Switzerland and is headquartered in Basel, Switzerland.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cellestia Biotech your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Cellestia Biotech
Product Launch: Get notified when Cellestia Biotech launches new products
Funding: Get notified immidiatlly once Cellestia Biotech has new funding data
Check out if Cellestia Biotech is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Cellestia Biotech has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Cellestia Biotech, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Cellestia Biotech had a recent Job posting/layoffs
Earning: See what the market has to say on Cellestia Biotech recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
Cellestia Biotech is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Cellestia Biotech is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Cellestia Biotech.
Cellestia Biotech financials insights
Gather financial insights about Cellestia Biotech, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Angel/Seed
$5.2M
2018
Series A
$21.3M
2019
Series B
$20.4M
Cellestia Biotech Tech Stack
A closer look at the technologies used by Cellestia Biotech
See more technologies
Most Recent Scoops
Event
Events
Left Company
Executive Move
Event
will be attending the 2022 BIO International Convention conference as an exhibitor. The event will occur from June 13 to June 16, 2022.
Funding
Funding
Cellestia Biotech News & Media
Cellestia Biotech Closes CHF20M Series B Financing
Cellestia Biotech, a Basel, Switzerland-based clinical-stage biopharma company, closed a CHF20m Series B funding round. The round was led by FC Capital, with participation from PPF Group, Partners Investment, and existing and new private investors. In conjunction with the funding, Guido Guidi and Robert Karsunky joined Cellestia’s Board of Directors. The funds will be added […] The post Cellestia Biotech Closes CHF20M Series B Financing appeared first on FinSMEs.Cellestia Biotech AG successfully closes Series B financing round, raising a total of CHF 20 million
BASEL, Switzerland--(BUSINESS WIRE)--Cellestia series B announcement release - 17 December 2019Cellestia Biotech AG successfully closes Series B financing round, raising a total of CHF 20 million
Cellestia series B announcement release - 17 December 2019
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Cellestia Biotech
Sign Up For FreeTo access detailed company insights
Cellestia is a clinical stage R&D company developing innovative first-in-class therapies to control and modulate pathogenic gene expression in multiple disease areas by selective inhibition of transcription factors in the cell nucleus. The lead compound CB-103 has advanced to Phase 2 successfully treating patients with multi-drug resistant cancers.... Read More
